- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03220971
Lipoprotein and Apolipoproteins With Metabolic Liver Diseases
April 17, 2018 updated by: Chun-Hsiang Wang
Theranostic Translation Applications Against Viral, Metabolic Liver Diseases and Hepatic Oncogenesis: Lipoprotein and Apolipoproteins at a Crossroad
Theranostic translation applications against viral, metabolic liver diseases and hepatic oncogenesis: lipoprotein and apolipoproteins at a crossroad
Study Overview
Status
Unknown
Intervention / Treatment
Detailed Description
An intimate link between microbial infections, metabolic changes and oncogenesis has been drawn attentions increasingly, indicating a crossroad leading to pathogenesis and disease progression.
Globally the burden of hepatitis B and C virus infections is 450 and 185 millions, respectively and chronic hepatitis disease causes a high risk of liver cirrhosis, hepatocellular carcinoma and metabolic disorders
Study Type
Observational
Enrollment (Anticipated)
440
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tainan, Taiwan, 701
- Chun-Hsiang Wang
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
An intimate link between microbial infections, metabolic changes and oncogenesis has been drawn attentions increasingly, indicating a crossroad leading to pathogenesis and disease progression.
Globally the burden of hepatitis B and C virus infections is 450 and 185 millions, respectively and chronic hepatitis disease causes a high risk of liver cirrhosis, hepatocellular carcinoma and metabolic disorders
Description
Inclusion Criteria:
- above 20 years
- nonalcoholic fatty liver disease
- Non-Alcoholic Steatohepatitis
Exclusion Criteria:
1. alcohonic hepatitis 2. Autoimmune liver disease 3. HIV postive
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
proposed cross-section study
|
To find out the role of lipoprotein and apolipoproteins (apos) in pathogenic hepatic diseases
|
proposed longitudinal study
|
To find out the role of lipoprotein and apolipoproteins (apos) in pathogenic hepatic diseases
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Theranostic Translation Applications Against Viral, Metabolic Liver Diseases and Hepatic Oncogenesis: Lipoprotein and Apolipoproteins at a Crossroad
Time Frame: 2years
|
Study the interplay between hepatitis C virus (HCV) and lipid metabolism(the HCV infection affects host lipid homeostasis, regarding transportation, synthesis, and catabolism.)
|
2years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 20, 2017
Primary Completion (Anticipated)
October 1, 2019
Study Completion (Anticipated)
October 1, 2019
Study Registration Dates
First Submitted
July 3, 2017
First Submitted That Met QC Criteria
July 13, 2017
First Posted (Actual)
July 18, 2017
Study Record Updates
Last Update Posted (Actual)
April 19, 2018
Last Update Submitted That Met QC Criteria
April 17, 2018
Last Verified
April 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1060603
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Disorders of Lipoprotein Metabolism and Other Lipidaemias
-
Texas A&M UniversityCompletedLipoprotein Metabolism Disorder
-
Amsterdam Molecular TherapeuticsInternational Antiviral Therapy Evaluation CenterUnknownFamilial Lipoprotein Lipase DeficiencyCanada
-
Amsterdam Molecular TherapeuticsThe Clinical Trial CompanyCompletedFamilial Lipoprotein Lipase DeficiencyCanada
-
Pamukkale UniversityBakirkoy Dr. Sadi Konuk Research and Training HospitalCompletedType2 Diabetes | Self Efficacy | Self Management | Cholesterol; Lipidosis | High Density Lipoprotein Deficiency | Motivational Interview | Tele-nursing | LDL - Low Density Lipoprotein Receptor DisorderTurkey
-
Nina HermansUniversity Hospital, AntwerpRecruitingLow-Density-Lipoprotein-Type [LDL] HyperlipoproteinemiaBelgium
-
Akcea TherapeuticsIonis Pharmaceuticals, Inc.CompletedCardiovascular Disease | Elevated Lipoprotein(a)United States, Canada, Denmark, Germany, Netherlands
-
Wake Forest University Health SciencesCompletedCardiovascular Diseases | Diabetes | Metabolic Syndrome | Liver Fat | Cardiovascular Risk Factor | Diet Habit | Dietary Modification | High Cholesterol | Triglycerides High | Low-density-lipoprotein-type | HDL Cholesterol, Low Serum | High Blood Sugar | Intra-abdominal Fat | High Density Lipoprotein DeficiencyUnited States
-
Technische Universität DresdenKaneka Pharma Europe N.V.RecruitingLipoprotein Types--Lp System Lp(A) HyperlipoproteinemiaGermany
-
Rottapharm SpainCentro Tecnológico de Nutrición y SaludCompletedHyperlipidemia | Elevated Triglycerides | Low-density-lipoprotein-typeSpain
-
Changi General HospitalNot yet recruitingCardiovascular Diseases | Hypercholesterolemia | Lipoprotein Types--Lp System Lp(A) HyperlipoproteinemiaSingapore
Clinical Trials on lipoprotein and apolipoproteins
-
Fresenius Medical Care Deutschland GmbHCompletedCardiovascular Diseases | Dyslipidemias | Hypercholesterolemia, FamilialGermany
-
Centre Hospitalier Universitaire de NiceRecruiting
-
Karolinska InstitutetRecruitingCardiovascular Diseases | Dyslipidemias | Hereditary DiseasesSweden
-
Imperial College LondonNational Institute for Health Research, United KingdomCompletedRefractory Angina | Raised Lipoprotein(a)>50mg/dL or >500mg/LUnited Kingdom
-
Centre Hospitalier Universitaire de la RéunionRecruitingCardiovascular DiseaseFrance
-
Fresenius Medical Care Deutschland GmbHCompletedHypercholesterolemia, Familial | LIPOPROTEIN TYPES--Lp SYSTEM Lp(a) HYPERLIPOPROTEINEMIAGermany
-
CSL LimitedCompletedStable Atherothrombotic DiseaseUnited States
-
General Hospital of Shenyang Military RegionTerminated
-
Tang-Du HospitalAir Force Military Medical University, ChinaNot yet recruiting